1. Combined Interventions for Severe Novel Coronavirus Disease (COVID-19): Experience from 350 Patients
- Author
-
Wei Guo, Hong Luo, Qingwu Qin, Nanyang Zeng, Zhiguo Zhou, Wenlong He, Ting Guo, Qinxue Shen, Peng Huang, Yunnian Wang, Jinhua Li, Hong Peng, Zhi Xiang, and Ping Chen
- Subjects
Pharmacology ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,Medical record ,Antibiotics ,Lopinavir ,macromolecular substances ,Disease ,medicine.disease ,Pneumonia ,Infectious Diseases ,Moxifloxacin ,Internal medicine ,medicine ,Corticosteroid ,Pharmacology (medical) ,Ritonavir ,business ,medicine.drug - Abstract
PURPOSE: To summarize the clinical features and effective therapy of severe COVID-19 patients PATIENTS AND METHODS: In this retrospective, multicenter study, the medical records of COVID-19 patients in Hunan, from January 21, 2020 to February 19, 2020 were reviewed RESULTS: Of the 350 COVID-19 patients, 13 7% were severe cases On admission, compared with non-severe patients, more severe patients had a neutrophil/lymphocyte ratio > 3 (58 3% vs 33 8%, P=0 001), D-dimer > 1 mg/L (41 7% vs 13 6%, P
- Published
- 2020